Cargando…
Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals
The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk(®)), estimates CV risk throughout a subjects’ lifetime, allowing those....
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859270/ https://www.ncbi.nlm.nih.gov/pubmed/29555916 http://dx.doi.org/10.1038/s41598-018-23037-7 |
_version_ | 1783307788068323328 |
---|---|
author | Baldan-Martin, Montserrat Lopez, Juan A. Corbacho-Alonso, Nerea Martinez, Paula J. Rodriguez-Sanchez, Elena Mourino-Alvarez, Laura Sastre-Oliva, Tamara Martin-Rojas, Tatiana Rincón, Raul Calvo, Eva Vazquez, Jesus Vivanco, Fernando Padial, Luis R. Alvarez-Llamas, Gloria Ruiz-Hurtado, Gema Ruilope, Luis M. Barderas, Maria G. |
author_facet | Baldan-Martin, Montserrat Lopez, Juan A. Corbacho-Alonso, Nerea Martinez, Paula J. Rodriguez-Sanchez, Elena Mourino-Alvarez, Laura Sastre-Oliva, Tamara Martin-Rojas, Tatiana Rincón, Raul Calvo, Eva Vazquez, Jesus Vivanco, Fernando Padial, Luis R. Alvarez-Llamas, Gloria Ruiz-Hurtado, Gema Ruilope, Luis M. Barderas, Maria G. |
author_sort | Baldan-Martin, Montserrat |
collection | PubMed |
description | The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk(®)), estimates CV risk throughout a subjects’ lifetime, allowing those. A more aggressive and earlier intervention to be identified and offered protection from the consequences of CV and renal disease. The search for molecular profiles in young people that allow a correct stratification of CV risk would be of great interest to adopt preventive therapeutic measures in individuals at high CV risk. To improve the selection of subjects susceptible to intervention with aged between 30–50 years, we have employed a multiple proteomic strategy to search for new markers of early CV disease or reported CV events and to evaluate their relationship with Lifetime Risk. Blood samples from 71 patients were classified into 3 groups according to their CV risk (healthy, with CV risk factors and with a previously reported CV event subjects) and they were analyzed using a high through quantitative proteomics approach. This strategy allowed three different proteomic signatures to be defined, two of which were related to CV stratification and the third one involved markers of organ damage. |
format | Online Article Text |
id | pubmed-5859270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58592702018-03-20 Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals Baldan-Martin, Montserrat Lopez, Juan A. Corbacho-Alonso, Nerea Martinez, Paula J. Rodriguez-Sanchez, Elena Mourino-Alvarez, Laura Sastre-Oliva, Tamara Martin-Rojas, Tatiana Rincón, Raul Calvo, Eva Vazquez, Jesus Vivanco, Fernando Padial, Luis R. Alvarez-Llamas, Gloria Ruiz-Hurtado, Gema Ruilope, Luis M. Barderas, Maria G. Sci Rep Article The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk(®)), estimates CV risk throughout a subjects’ lifetime, allowing those. A more aggressive and earlier intervention to be identified and offered protection from the consequences of CV and renal disease. The search for molecular profiles in young people that allow a correct stratification of CV risk would be of great interest to adopt preventive therapeutic measures in individuals at high CV risk. To improve the selection of subjects susceptible to intervention with aged between 30–50 years, we have employed a multiple proteomic strategy to search for new markers of early CV disease or reported CV events and to evaluate their relationship with Lifetime Risk. Blood samples from 71 patients were classified into 3 groups according to their CV risk (healthy, with CV risk factors and with a previously reported CV event subjects) and they were analyzed using a high through quantitative proteomics approach. This strategy allowed three different proteomic signatures to be defined, two of which were related to CV stratification and the third one involved markers of organ damage. Nature Publishing Group UK 2018-03-19 /pmc/articles/PMC5859270/ /pubmed/29555916 http://dx.doi.org/10.1038/s41598-018-23037-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Baldan-Martin, Montserrat Lopez, Juan A. Corbacho-Alonso, Nerea Martinez, Paula J. Rodriguez-Sanchez, Elena Mourino-Alvarez, Laura Sastre-Oliva, Tamara Martin-Rojas, Tatiana Rincón, Raul Calvo, Eva Vazquez, Jesus Vivanco, Fernando Padial, Luis R. Alvarez-Llamas, Gloria Ruiz-Hurtado, Gema Ruilope, Luis M. Barderas, Maria G. Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals |
title | Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals |
title_full | Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals |
title_fullStr | Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals |
title_full_unstemmed | Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals |
title_short | Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals |
title_sort | potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859270/ https://www.ncbi.nlm.nih.gov/pubmed/29555916 http://dx.doi.org/10.1038/s41598-018-23037-7 |
work_keys_str_mv | AT baldanmartinmontserrat potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT lopezjuana potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT corbachoalonsonerea potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT martinezpaulaj potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT rodriguezsanchezelena potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT mourinoalvarezlaura potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT sastreolivatamara potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT martinrojastatiana potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT rinconraul potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT calvoeva potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT vazquezjesus potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT vivancofernando potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT padialluisr potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT alvarezllamasgloria potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT ruizhurtadogema potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT ruilopeluism potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals AT barderasmariag potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals |